References
- Cerny T, Borisch B, Introna M, Johnson P, Rose A L. Mechanism of action of rituximab. Anticancer Drugs 2002; 13(Suppl 2)S3–S10
- Czuczman M S, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694–704
- Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line chemotherapy for advanced follicular lymphoma. Blood 2005; 195: 1417–1423
- Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253
- Okamoto T, Nishimura Y, Yamada S, Yamada S, Itoh T, Mori A, et al. Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma. Acta Haematol 2000; 104: 128–130
- Hainsworth J D. Prolonging remission with rituximab maintenance therapy. Semin Oncol 2004; 31: 17–21
- Kornblau S M, Konopleva M, Andreeff M. Apoptosis regulating proteins as targets of therapy for haematological malignancies. Expert Opin Invest Drugs 1999; 8: 2027–2057
- Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 2000; 20: 2961–2966
- Di Gaetano N, Xiao Y, Erba E, Bassan R, Rambaldi A, Golay J. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800–809
- Jovasevic V M, Mokyr M B. Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression. J Immunol 2001; 167: 4895–4901
- Donepudi M, Raychaudhuri P, Bluestone J A, Mokyr M B. Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells. J Immunol 2001; 166: 6491–6499
- Weiskirch L M, Bar-Dagan Y, Mokyr M B. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. Cancer Immunol Immunother 1994; 38: 215–224
- Gianni A M, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting. Blood 2003; 102: 749–755
- Voso M T, Pantel G, Rutella S, Weis N, D'Alo F, Urbano R, et al. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica 2002; 87: 918–925
- Pose A L, Smith B E, Maloney D G. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 2002; 100: 1765–1773